Chugai Pharmaceutical (OTCMKTS:CHGCY) Sees Unusually-High Trading Volume - Still a Buy?

Shares of Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY - Get Free Report) saw unusually-high trading volume on Tuesday . Approximately 314,453 shares were traded during mid-day trading, an increase of 70% from the previous session's volume of 185,137 shares.The stock last traded at $23.50 and had previously closed at $24.38.

Chugai Pharmaceutical Trading Down 3.5%

The firm has a market cap of $77.41 billion, a P/E ratio of 29.04 and a beta of 0.66. The business's fifty day simple moving average is $26.32 and its 200-day simple moving average is $24.36.

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The company reported $0.19 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a net margin of 33.56% and a return on equity of 21.71%. The company had revenue of $1.89 billion for the quarter. Analysts anticipate that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.